Pulmonary Complications of Cancer: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<div class="editorbox"> '''Original Editor '''- [[User:Donald John Auson|Donald John Auson]] '''Top Contributors''' - {{Special:Contributors/{{FULLPAGENAME}}}}</div> | |||
<div class="noeditbox">This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! ({{REVISIONDAY}}/{{REVISIONMONTH}}/{{REVISIONYEAR}})</div>Infectious Complications | <div class="noeditbox">This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! ({{REVISIONDAY}}/{{REVISIONMONTH}}/{{REVISIONYEAR}})</div>Infectious Complications | ||
Revision as of 05:04, 3 July 2020
Infectious Complications
Bacterial Infection
Viral Infection
Fungal Infection
Protozoal Infection
Non-Infectious Complications
Metastatic Disease
Obstructive Lung Disease
Restrictive Lung Disease
Radiation Therapy Complications
Radiation Pneumonitis
Chemotherapy Complications
Chemotherapy Pneumonitis
Pulmonary Vascular Disease
Drug Toxicities
Certain drugs have been shown to increase the risk for the development of pulmonary complications such as respiratory failure.[1] This include tyrosine kinase inhibitors, mTOR kinase inhibitors, monoclonal antibody, taxanes. A study showed that exposure to one of more of these medications was a significant risk factor in the development of respiratory failure.[1]
Rehabilitation Treatment
Considerations
- ↑ 1.0 1.1 Brown, Anne Rain; Bruno, Jeffrey; Nates, Joseph 1239: PULMONARY COMPLICATIONS IN CANCER PATIENTS: NOVEL DRUGS WITH NEW TOXICITIES, Critical Care Medicine: January 2018 - Volume 46 - Issue 1 - p 603 doi: 10.1097/01.ccm.0000529242.93804.d6 Available at https://journals.lww.com/ccmjournal/Citation/2018/01001/1239__PULMONARY_COMPLICATIONS_IN_CANCER_PATIENTS_.1193.aspx
